Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AGEN
AGEN logo

AGEN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Agenus Inc (AGEN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
3.500
1 Day change
2.94%
52 Week Range
7.340
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

AGEN is not a good buy right now for a beginner with a long-term focus and $50,000-$100,000 to invest. The stock is showing a weak technical setup, there is no recent news catalyst, no positive proprietary trading signal, and the short-term pattern analysis points to further downside. Based on the current data, I would not buy it now.

Technical Analysis

The technical picture is bearish. MACD histogram is negative and still contracting, RSI_6 at 53.6 is neutral, and the moving averages are in a bearish alignment with SMA_200 > SMA_20 > SMA_5. Price at 3.40 is only slightly above pivot support at 3.312, with nearby downside levels at S1 3.083 and S2 2.941. Resistance is at 3.541 and 3.683, so upside is limited while downside remains open. The stock trend model also suggests a 60% chance of declines over the next day, week, and month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment looks mildly bullish on positioning because the put-call open interest ratio is low at 0.22, but the trading flow is not strong enough to override the weak chart. Call open interest (4619) is higher than put open interest (1002), yet option volume is light and put/call volume is 0, which makes the sentiment read less convincing. IV is elevated (30D IV 120.27), suggesting the market is pricing in large moves, but not necessarily a positive one.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
3

Positive Catalysts

  • The only mild positive is the option positioning, where call open interest exceeds put open interest and the put-call ratio is low. The stock is also not showing any major negative news event right now because there has been no news in the past week.

Neutral/Negative Catalysts

  • No news in recent week means there is no fresh catalyst to drive a rebound. Hedge funds are neutral and insiders are neutral, so there is no strong accumulation signal. AI Stock Picker has no signal today, and SwingMax has no signal recently. The historical pattern analysis is negative, pointing to likely near-term weakness.

Financial Performance

Latest quarter financial data was not available because the snapshot returned an error, so there is no usable recent-quarter growth readout. Because the latest quarterly results cannot be confirmed, there is no financial momentum evidence supporting a new long-term purchase from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no evidence of a recent positive trend in Wall Street estimates. From the available information, the pro view is weak because there is no supporting catalyst, no positive revision trend, and no strong institutional or insider buying. The con view is stronger: bearish technicals, lack of news, and no proprietary buy signal.

Wall Street analysts forecast AGEN stock price to rise
1 Analyst Rating
Wall Street analysts forecast AGEN stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.400
sliders
Low
23
Averages
23
High
23
Current: 3.400
sliders
Low
23
Averages
23
High
23
H.C. Wainwright
H.C. Wainwright
Neutral -> Buy
upgrade
$25
AI Analysis
2025-06-04
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$25
AI Analysis
2025-06-04
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded Agenus to Buy from Neutral with a $25 price target after the company entered into a strategic collaboration with Indian multinational pharmaceutical company Zydus Lifesciences. The definitive partnership is valued at up to $141M and is aimed at accelerating the clinical development of botensilimab and balstilimab while also securing scaled manufacturing both domestically and outside the U.S., the analyst tells investors in a research note. Th firm says that given Agenus' commitment to reducing its cash burn and the capital provided from this partnership, it now believes the company has sufficient funding to advance botensilimab and balstilimab through a Phase 3 trial initiating in the second half of 2025.
Baird
Baird
Neutral
maintain
$4 -> $6
2025-06-04
Reason
Baird
Baird
Price Target
$4 -> $6
2025-06-04
maintain
Neutral
Reason
Baird raised the firm's price target on Agenus to $6 from $4 and keeps a Neutral rating on the shares. The firm updatedits model following the receipt of ts $91M upfront payment from its strategic collaboration with Zydus.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AGEN
Unlock Now

People Also Watch